Novartis International AG /Novartis gains positive CHMP opinion for Gilenya®, first oral multiple sclerosis treatment recommended for approval in the European Union Processed and transmitted by Thomson Reuters.the issuer is solely responsible for the content of this announcement.
* Gilenya recommended in the EU for people with highly active relapsing- remitting MS despite treatment with beta interferon, or in patients with rapidly evolving severe relapsing-remitting MS
* Gilenya showed superior efficacy to interferon beta-1a IM, a commonly prescribed treatment, reducing relapses by 52% (p